Christine T Mui
Examiner (ID: 2758, Phone: (571)270-3243 , Office: P/1797 )
Most Active Art Unit | 1797 |
Art Unit(s) | 1774, 1709, 1797, 1777 |
Total Applications | 1433 |
Issued Applications | 1052 |
Pending Applications | 84 |
Abandoned Applications | 297 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 19090986
[patent_doc_number] => 11952416
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-04-09
[patent_title] => Anti-annexin A1 antibodies
[patent_app_type] => utility
[patent_app_number] => 18/467405
[patent_app_country] => US
[patent_app_date] => 2023-09-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 16
[patent_no_of_words] => 10171
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 90
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18467405
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/467405 | Anti-annexin A1 antibodies | Sep 13, 2023 | Issued |
Array
(
[id] => 18568320
[patent_doc_number] => 20230258656
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-17
[patent_title] => CATABODIES AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/045114
[patent_app_country] => US
[patent_app_date] => 2022-10-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38134
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 137
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18045114
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/045114 | CATABODIES AND METHODS OF USE THEREOF | Oct 6, 2022 | Pending |
Array
(
[id] => 18070584
[patent_doc_number] => 11529400
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2022-12-20
[patent_title] => Personalized immunotherapy against several neuronal and brain tumors
[patent_app_type] => utility
[patent_app_number] => 17/852206
[patent_app_country] => US
[patent_app_date] => 2022-06-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 81402
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17852206
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/852206 | Personalized immunotherapy against several neuronal and brain tumors | Jun 27, 2022 | Issued |
Array
(
[id] => 18070585
[patent_doc_number] => 11529401
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-12-20
[patent_title] => Personalized immunotherapy against several neuronal and brain tumors
[patent_app_type] => utility
[patent_app_number] => 17/852207
[patent_app_country] => US
[patent_app_date] => 2022-06-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 81445
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17852207
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/852207 | Personalized immunotherapy against several neuronal and brain tumors | Jun 27, 2022 | Issued |
Array
(
[id] => 18050692
[patent_doc_number] => 11524059
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-12-13
[patent_title] => Personalized immunotherapy against several neuronal and brain tumors
[patent_app_type] => utility
[patent_app_number] => 17/852205
[patent_app_country] => US
[patent_app_date] => 2022-06-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 81395
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17852205
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/852205 | Personalized immunotherapy against several neuronal and brain tumors | Jun 27, 2022 | Issued |
Array
(
[id] => 18634936
[patent_doc_number] => 11759507
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-09-19
[patent_title] => Personalized immunotherapy against several neuronal and brain tumors
[patent_app_type] => utility
[patent_app_number] => 17/851417
[patent_app_country] => US
[patent_app_date] => 2022-06-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 11
[patent_no_of_words] => 81237
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17851417
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/851417 | Personalized immunotherapy against several neuronal and brain tumors | Jun 27, 2022 | Issued |
Array
(
[id] => 18295925
[patent_doc_number] => 20230105611
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-06
[patent_title] => COMBINATION THERAPY WITH CGRP ANTAGONISTS AND CLOSTRIDIAL DERIVATIVES
[patent_app_type] => utility
[patent_app_number] => 17/734531
[patent_app_country] => US
[patent_app_date] => 2022-05-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11749
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17734531
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/734531 | COMBINATION THERAPY WITH CGRP ANTAGONISTS AND CLOSTRIDIAL DERIVATIVES | May 1, 2022 | Pending |
Array
(
[id] => 17990182
[patent_doc_number] => 20220356219
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-10
[patent_title] => CHIMERIC PROTEIN IN THE TREATMENT OF AMYLOIDOSIS
[patent_app_type] => utility
[patent_app_number] => 17/729534
[patent_app_country] => US
[patent_app_date] => 2022-04-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19024
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -1
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17729534
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/729534 | CHIMERIC PROTEIN IN THE TREATMENT OF AMYLOIDOSIS | Apr 25, 2022 | Pending |
Array
(
[id] => 18036240
[patent_doc_number] => 20220380455
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-01
[patent_title] => ANTI-MS4A6A ANTIBODIES AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/722624
[patent_app_country] => US
[patent_app_date] => 2022-04-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 45562
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17722624
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/722624 | ANTI-MS4A6A ANTIBODIES AND METHODS OF USE THEREOF | Apr 17, 2022 | Pending |
Array
(
[id] => 18145746
[patent_doc_number] => 20230019602
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-19
[patent_title] => METHODS FOR TREATMENT OF MOTOR NEURON DISEASES
[patent_app_type] => utility
[patent_app_number] => 17/688717
[patent_app_country] => US
[patent_app_date] => 2022-03-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14983
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17688717
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/688717 | METHODS FOR TREATMENT OF MOTOR NEURON DISEASES | Mar 6, 2022 | Pending |
Array
(
[id] => 17881260
[patent_doc_number] => 20220296737
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-22
[patent_title] => IMMUNOPET AND IMMUNOSPECT IMAGING TO IDENTIFY CYTOTOXIC T CELL ACTIVITY
[patent_app_type] => utility
[patent_app_number] => 17/686230
[patent_app_country] => US
[patent_app_date] => 2022-03-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9675
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 102
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17686230
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/686230 | IMMUNOPET AND IMMUNOSPECT IMAGING TO IDENTIFY CYTOTOXIC T CELL ACTIVITY | Mar 2, 2022 | Pending |
Array
(
[id] => 18567121
[patent_doc_number] => 20230257450
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-17
[patent_title] => antiRPS4Y1 mAb
[patent_app_type] => utility
[patent_app_number] => 17/673912
[patent_app_country] => US
[patent_app_date] => 2022-02-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3695
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17673912
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/673912 | antiRPS4Y1 mAb | Feb 16, 2022 | Pending |
Array
(
[id] => 19210737
[patent_doc_number] => 11999785
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-06-04
[patent_title] => Binding molecule specific for Lrig-1 protein and use thereof
[patent_app_type] => utility
[patent_app_number] => 17/672208
[patent_app_country] => US
[patent_app_date] => 2022-02-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 13
[patent_no_of_words] => 11243
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17672208
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/672208 | Binding molecule specific for Lrig-1 protein and use thereof | Feb 14, 2022 | Issued |
Array
(
[id] => 17911279
[patent_doc_number] => 20220313674
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-06
[patent_title] => PSILOCYBIN COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 17/669845
[patent_app_country] => US
[patent_app_date] => 2022-02-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5453
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 11
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17669845
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/669845 | PSILOCYBIN COMPOSITIONS | Feb 10, 2022 | Pending |
Array
(
[id] => 17627245
[patent_doc_number] => 20220162260
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-26
[patent_title] => USE OF LOW PH AND DEXTRAN SULFATE DURING HARVEST TREATMENT FOR PROTEIN PURIFICATION
[patent_app_type] => utility
[patent_app_number] => 17/666891
[patent_app_country] => US
[patent_app_date] => 2022-02-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8690
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17666891
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/666891 | USE OF LOW PH AND DEXTRAN SULFATE DURING HARVEST TREATMENT FOR PROTEIN PURIFICATION | Feb 7, 2022 | Pending |
Array
(
[id] => 17627287
[patent_doc_number] => 20220162302
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-26
[patent_title] => ANTIBODIES USEFUL IN CANCER DIAGNOSIS
[patent_app_type] => utility
[patent_app_number] => 17/666122
[patent_app_country] => US
[patent_app_date] => 2022-02-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25590
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17666122
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/666122 | Antibodies useful in cancer diagnosis | Feb 6, 2022 | Issued |
Array
(
[id] => 17595356
[patent_doc_number] => 20220144929
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-12
[patent_title] => ANTI-SEMA3A ANTIBODIES AND THEIR USES FOR TREATING EYE OR OCULAR DISEASES
[patent_app_type] => utility
[patent_app_number] => 17/583245
[patent_app_country] => US
[patent_app_date] => 2022-01-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19984
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17583245
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/583245 | ANTI-SEMA3A ANTIBODIES AND THEIR USES FOR TREATING EYE OR OCULAR DISEASES | Jan 24, 2022 | Pending |
Array
(
[id] => 17929783
[patent_doc_number] => 20220324908
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-13
[patent_title] => ADVANTAGEOUS SALTS OF MU-OPIATE RECEPTOR PEPTIDES
[patent_app_type] => utility
[patent_app_number] => 17/554421
[patent_app_country] => US
[patent_app_date] => 2021-12-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8292
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17554421
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/554421 | ADVANTAGEOUS SALTS OF MU-OPIATE RECEPTOR PEPTIDES | Dec 16, 2021 | Pending |
Array
(
[id] => 17627278
[patent_doc_number] => 20220162293
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-26
[patent_title] => EPITOPES IN THE RNA RECOGNITION MOTIF 1 (RRM1) OF TDP-43 AND MISFOLDING-SELECTIVE ANTIBODIES THERETO
[patent_app_type] => utility
[patent_app_number] => 17/541812
[patent_app_country] => US
[patent_app_date] => 2021-12-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30914
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17541812
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/541812 | EPITOPES IN THE RNA RECOGNITION MOTIF 1 (RRM1) OF TDP-43 AND MISFOLDING-SELECTIVE ANTIBODIES THERETO | Dec 2, 2021 | Pending |
Array
(
[id] => 17595355
[patent_doc_number] => 20220144928
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-12
[patent_title] => ANTIBODY-BASED THERAPY OF TRANSTHYRETIN (TTR) AMYLOIDOSIS AND HUMAN-DERIVED ANTIBODIES THEREFOR
[patent_app_type] => utility
[patent_app_number] => 17/532292
[patent_app_country] => US
[patent_app_date] => 2021-11-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 48746
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17532292
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/532292 | ANTIBODY-BASED THERAPY OF TRANSTHYRETIN (TTR) AMYLOIDOSIS AND HUMAN-DERIVED ANTIBODIES THEREFOR | Nov 21, 2021 | Pending |